期刊文献+

Solid-state characterization and impurities determination of fluconazol generic products marketed in Morocco 被引量:3

Solid-state characterization and impurities determination of fluconazol generic products marketed in Morocco
下载PDF
导出
摘要 In this paper, we report the results of quality control based in pbysicochemical characteriza- tion and impurities determination of three samples of fluconazole drug substances marketed in Morocco. These samples were supplied by different pharmaceuticals companies. The sample A, as the discovered product, was supplied by Pfizer, while samples B and C (generics), were manufactured by two different Indian industries. Solid-state characterization of the three samples was realized with different physicochemical methods as: X-ray powder diffraction, Fourier-transformation infrared spectroscopy, differential scanning calorimetry. High performance liquid chromatography was used to quantify the impurities in the different samples. The results from the physicochemical methods cited above, showed difference in polymorph structure of the three drug substances. Sample A consisted in pure polymorph II1, sample B consisted in pure polymorph I1, sample C consisted in a mixture of fluconazole Form Ili, form II and the monohydrate. This result was confirmed by differential scanning calorimetry. Also it was demonstrated that solvents used during the re-crystallization step were among the origins of these differences in the structure form. On the other hand, the result of the stability study under humidity and temperature showed that fluconazole polymorphic transformation could be owed to the no compliance with the conditions of storage. The HPLC analysis of these compounds showed the presence of specific In this paper, we report the results of quality control based in pbysicochemical characteriza- tion and impurities determination of three samples of fluconazole drug substances marketed in Morocco. These samples were supplied by different pharmaceuticals companies. The sample A, as the discovered product, was supplied by Pfizer, while samples B and C (generics), were manufactured by two different Indian industries. Solid-state characterization of the three samples was realized with different physicochemical methods as: X-ray powder diffraction, Fourier-transformation infrared spectroscopy, differential scanning calorimetry. High performance liquid chromatography was used to quantify the impurities in the different samples. The results from the physicochemical methods cited above, showed difference in polymorph structure of the three drug substances. Sample A consisted in pure polymorph II1, sample B consisted in pure polymorph I1, sample C consisted in a mixture of fluconazole Form Ili, form II and the monohydrate. This result was confirmed by differential scanning calorimetry. Also it was demonstrated that solvents used during the re-crystallization step were among the origins of these differences in the structure form. On the other hand, the result of the stability study under humidity and temperature showed that fluconazole polymorphic transformation could be owed to the no compliance with the conditions of storage. The HPLC analysis of these compounds showed the presence of specific
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2012年第6期412-421,共10页 药物分析学报(英文版)
关键词 Generic productQuality control FLUCONAZOLE POLYMORPHISM IMPURITIES Generic productQuality control Fluconazole Polymorphism Impurities
  • 相关文献

参考文献24

  • 1S.R. Vippagunta, H.G. Brittain, D.J.W. Granta, Crystalline solids, Adv. Drug Delivery Rev. 48 (2001) 3-26.
  • 2D. Singhal, W. Curatolo, Advanced polymorphism and dosage form design: a practical perspective, Drug Delivery Rev. 56 (2004) 335-347.
  • 3M. Bauer, L. de Leede, M. Van Der Waart, Conference Report: Purity as an Issue in Pharmaceutical Research and Development, Eur. J .Pharm Sci. 6 (1998) 331- 335.
  • 4L.F. Huang, W.Q. Tong, Impact of solid state properties on developability assessment of drug candidates, Adv. Drug Delivery Rev. 56 (2004) 321-334.
  • 5D.J. Sheehan, C.A. Hitchcock, C.M. Sibley, Current and Emer- ging Azole Antifungal Agents, Clin. Microbiol. Rev. 12 (1) (1999) 40-79.
  • 6T.D.H Vensel, Fluconazole: a valuable fungistatic, Antibiot. Rev. 9 (5) (2002) 181-183.
  • 7J.J. Stern, B.J. Hartman, P. Sharkey, et al., Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients, Am. J. Med. 85 (1988) 477-480.
  • 8R.J. Hay, Fluconazole, J. Infec. 21 (1990) 1-6.
  • 9O. Petitjean, A. Jacolot et, M. Tod, Pharmacologie des anti- fongiques azoles systemiques, Med. Mal. Infect. 25 (1995) 14-26.
  • 10M. Zervos, F. Meunier, Fluconazole (Diflucan ): a review, Int. J. Antimicrob Ag. 3 (1993) 147-170.

同被引文献10

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部